New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (kr1.3m revenue, or US$140k). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (kr123.3m market cap, or US$13.0m). Reported Earnings • May 24
First quarter 2026 earnings released: kr0.094 loss per share (vs kr0.10 loss in 1Q 2025) First quarter 2026 results: kr0.094 loss per share. Net loss: kr4.33m (loss widened 8.6% from 1Q 2025). Reported Earnings • Feb 22
Full year 2025 earnings released: kr0.45 loss per share (vs kr0.52 loss in FY 2024) Full year 2025 results: kr0.45 loss per share. Net loss: kr17.7m (loss widened 2.1% from FY 2024). New Risk • Jan 18
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m (kr1.3m revenue, or US$145k). Market cap is less than US$10m (kr87.1m market cap, or US$9.44m). Reported Earnings • Nov 24
Third quarter 2025 earnings released: kr0.11 loss per share (vs kr0.11 loss in 3Q 2024) Third quarter 2025 results: kr0.11 loss per share (further deteriorated from kr0.11 loss in 3Q 2024). Net loss: kr4.32m (loss widened 16% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. 공시 • Nov 07
Bioextrax AB (publ), Annual General Meeting, May 21, 2026 Bioextrax AB (publ), Annual General Meeting, May 21, 2026. New Risk • Sep 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (kr1.3m revenue, or US$136k). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (kr119.6m market cap, or US$12.8m). Reported Earnings • Aug 22
Second quarter 2025 earnings released: kr0.11 loss per share (vs kr0.15 loss in 2Q 2024) Second quarter 2025 results: kr0.11 loss per share (improved from kr0.15 loss in 2Q 2024). Net loss: kr4.38m (loss narrowed 8.7% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. New Risk • May 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (kr949k revenue, or US$98k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (kr126.7m market cap, or US$13.1m). Reported Earnings • May 19
First quarter 2025 earnings released: kr0.10 loss per share (vs kr0.17 loss in 1Q 2024) First quarter 2025 results: kr0.10 loss per share (improved from kr0.17 loss in 1Q 2024). Net loss: kr3.99m (loss narrowed 18% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. New Risk • Mar 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Revenue is less than US$1m (kr1.0m revenue, or US$101k). Market cap is less than US$10m (kr96.2m market cap, or US$9.62m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). New Risk • Feb 26
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (kr1.0m revenue, or US$95k). Market cap is less than US$10m (kr97.5m market cap, or US$9.19m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m (kr1.6m revenue, or US$143k). Market cap is less than US$10m (kr87.7m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Jan 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr109.4m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m (kr1.6m revenue, or US$142k). Market cap is less than US$10m (kr109.4m market cap, or US$9.86m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). Reported Earnings • Dec 01
Third quarter 2024 earnings released: kr0.11 loss per share (vs kr0.21 loss in 3Q 2023) Third quarter 2024 results: kr0.11 loss per share (improved from kr0.21 loss in 3Q 2023). Net loss: kr3.73m (loss narrowed 32% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. 공시 • Oct 25
Bioextrax AB (publ), Annual General Meeting, May 22, 2025 Bioextrax AB (publ), Annual General Meeting, May 22, 2025. Reported Earnings • Aug 21
Second quarter 2024 earnings released: kr0.15 loss per share (vs kr0.22 loss in 2Q 2023) Second quarter 2024 results: kr0.15 loss per share (improved from kr0.22 loss in 2Q 2023). Net loss: kr4.80m (loss narrowed 13% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings. New Risk • Aug 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (kr2.2m revenue, or US$205k). Minor Risks Shareholders have been diluted in the past year (35% increase in shares outstanding). Market cap is less than US$100m (kr123.3m market cap, or US$11.7m). New Risk • Aug 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr99.9m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (kr2.2m revenue, or US$204k). Market cap is less than US$10m (kr99.9m market cap, or US$9.46m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (35% increase in shares outstanding). Reported Earnings • May 20
First quarter 2024 earnings released: kr0.17 loss per share (vs kr0.17 loss in 1Q 2023) First quarter 2024 results: kr0.17 loss per share (further deteriorated from kr0.17 loss in 1Q 2023). Revenue: kr203.0k (down 81% from 1Q 2023). Net loss: kr4.87m (loss widened 15% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 18
Full year 2023 earnings released: kr0.81 loss per share (vs kr1.11 loss in FY 2022) Full year 2023 results: kr0.81 loss per share. Revenue: kr3.01m (up 37% from FY 2022). Net loss: kr21.5m (loss widened 15% from FY 2022). New Risk • Feb 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (kr2.9m revenue, or US$278k). Market cap is less than US$10m (kr55.8m market cap, or US$5.26m). Minor Risk Shareholders have been diluted in the past year (15% increase in shares outstanding). Reported Earnings • Nov 19
Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.30 loss in 3Q 2022) Third quarter 2023 results: kr0.21 loss per share. Net loss: kr5.50m (loss widened 20% from 3Q 2022). Reported Earnings • Aug 28
Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.36 loss in 2Q 2022) Second quarter 2023 results: kr0.22 loss per share (improved from kr0.36 loss in 2Q 2022). Net loss: kr5.54m (flat on 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. New Risk • Aug 15
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr107.7m (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$262k). Market cap is less than US$10m (kr107.7m market cap, or US$9.94m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change). New Risk • Jul 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr108.2m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$262k). Market cap is less than US$10m (kr108.2m market cap, or US$9.99m). Reported Earnings • Feb 19
Full year 2022 earnings released: kr1.11 loss per share (vs kr0.74 loss in FY 2021) Full year 2022 results: kr1.11 loss per share (further deteriorated from kr0.74 loss in FY 2021). Net loss: kr18.7m (loss widened 77% from FY 2021). Recent Insider Transactions • Jan 17
CTO & Director recently sold kr650k worth of stock On the 13th of January, Mohammad H. Ibrahim sold around 200k shares on-market at roughly kr3.25 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Dec 02
Third quarter 2022 earnings released Third quarter 2022 results: Net loss: kr4.60m (loss widened 80% from 3Q 2021). Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Reported Earnings • Jun 03
First quarter 2022 earnings released First quarter 2022 results: Net loss: kr2.78m (loss widened 37% from 1Q 2021). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Member of Advisory Board Jan Ravenstijn was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Is New 90 Day High Low • Feb 12
New 90-day high: kr103 The company is up 128% from its price of kr45.20 on 13 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. Is New 90 Day High Low • Jan 20
New 90-day high: kr93.40 The company is up 167% from its price of kr35.00 on 22 October 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. Is New 90 Day High Low • Dec 04
New 90-day high: kr78.60 The company is up 105% from its price of kr38.40 on 04 September 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period. Is New 90 Day High Low • Nov 10
New 90-day high: kr42.50 The company is up 30% from its price of kr32.70 on 12 August 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. 공시 • Oct 13
Bioextrax AB (publ) to Report Q3, 2020 Results on Nov 10, 2020 Bioextrax AB (publ) announced that they will report Q3, 2020 results on Nov 10, 2020 공시 • Sep 12
Bioextrax AB (publ) to Report Q2, 2020 Results on Aug 25, 2020 Bioextrax AB (publ) announced that they will report Q2, 2020 results on Aug 25, 2020